Angela Brennan
Acute Care · Dearborn Heights, MINPI 1679888630
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,306 and has fallen 99.2% since, to $18 in 2025. Among acute care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- UCB, Inc.$1K
- AbbVie$846
- Amgen$719
- Pfizer$485
- Biohaven Pharmaceutical Holding Company Ltd.$445
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,267100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 63 | $1,437 |
| UCB, Inc. | 48 | $1,004 |
| AbbVie(2 entities) | 63 | $846 |
| Amgen(2 entities) | 37 | $719 |
| Pfizer | 32 | $485 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $445 |
| Lilly USA, LLC | 12 | $308 |
| CSL Behring | 15 | $282 |
| Bristol Myers Squibb | 14 | $224 |
| Sumitomo Pharma America, Inc. | 11 | $210 |
| Supernus Pharmaceuticals, Inc. | 23 | $156 |
| Avanir Pharmaceuticals, Inc. | 14 | $133 |
| Teva Pharmaceuticals USA, Inc. | 8 | $127 |
| Kyowa Kirin, Inc. | 1 | $125 |
| Novartis | 8 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Genentech USA, Inc. | 3 | $59 |
| TG Therapeutics, Inc. | 3 | $52 |
| Lundbeck LLC | 2 | $46 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Impel Pharmaceuticals Inc. | 1 | $34 |
| Catalyst Pharmaceuticals, Inc. | 2 | $32 |
| Acorda Therapeutics, Inc | 2 | $31 |
| Corium, LLC | 3 | $30 |
| Neurelis, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| AstraZeneca | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$241
- KISUNLA$125
- AIMOVIG$125
- NOURIANZ$125
- DALVANCE$100
How this compares
$7,289 in reported general payments places this provider in the 95th percentile of 567 acute care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GilenyaFingolimod Hcl | 16 | $228,434 |
| VumerityDiroximel Fumarate | 19 | $194,514 |
| Nurtec OdtRimegepant Sulfate | 91 | $121,262 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $113,969 |
| BriviactBrivaracetam | 55 | $98,184 |
| IngrezzaValbenazine Tosylate | 12 | $97,179 |
| Emgality PenGalcanezumab-Gnlm | 105 | $97,009 |
| CopaxoneGlatiramer Acetate | 13 | $78,385 |
| AustedoDeutetrabenazine | 12 | $75,655 |
| Glatiramer Acetate | 14 | $66,591 |
| GlatopaGlatiramer Acetate | 14 | $59,359 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $41,967 |
| UbrelvyUbrogepant | 19 | $28,472 |
| Lacosamide | 202 | $15,525 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $14,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisGilenya | $125 | $228,43416 claims |
| BiogenVumerity | $1,437 | $194,51419 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $127 | $154,04025 claims |
| PfizerNurtec Odt | $485 | $121,26291 claims |
| UCB, Inc.Briviact | $1,004 | $98,18455 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $25 | $97,17912 claims |
| AbbVieUbrelvy | $846 | $28,47219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 acute care providers in Michigan.
Other acute care in Dearborn Heights
- Jennifer BrujitskeDearborn Heights$3K
- Janet WymanDetroit$103K
- Stephanie Mellon ReppenDetroit$57K
- Ashley WozniakLivonia$26K
- Julia BriggsBirch Run$16K
- Candise LovePort Huron$14K
- Janette GuertinPort Huron$14K
- Gregory AliNovi$13K
- Andrew PalmerLansing$9K
- Jennifer RutzenLansing$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.